Skip to main content
. 2023 Feb 2;29(2):473–482. doi: 10.1038/s41591-022-02179-2

Fig. 1. Trial profile.

Fig. 1

Among patients who were randomized to receive placebo plus chemotherapy, 15 received serplulimab plus chemotherapy because of an error in drug distribution.